Your browser is no longer supported. Please, upgrade your browser.
Settings
GNCA Genocea Biosciences, Inc. daily Stock Chart
GNCA [NASD]
Genocea Biosciences, Inc.
Index- P/E- EPS (ttm)-1.47 Insider Own0.20% Shs Outstand29.14M Perf Week-37.85%
Market Cap113.19M Forward P/E- EPS next Y-0.96 Insider Trans- Shs Float26.36M Perf Month51.46%
Income-41.10M PEG- EPS next Q-0.24 Inst Own48.00% Short Float1.10% Perf Quarter35.65%
Sales0.90M P/S125.77 EPS this Y30.00% Inst Trans0.26% Short Ratio0.26 Perf Half Y47.87%
Book/sh0.25 P/B12.48 EPS next Y21.30% ROA-83.10% Target Price- Perf Year2.97%
Cash/sh0.61 P/C5.12 EPS next 5Y- ROE-220.00% 52W Range1.10 - 5.75 Perf YTD50.72%
Dividend- P/FCF- EPS past 5Y36.40% ROI- 52W High-47.48% Beta2.48
Dividend %- Quick Ratio1.10 Sales past 5Y- Gross Margin- 52W Low174.55% ATR0.58
Employees59 Current Ratio1.10 Sales Q/Q- Oper. Margin- RSI (14)49.01 Volatility21.12% 16.15%
OptionableYes Debt/Eq1.88 EPS Q/Q8.20% Profit Margin- Rel Volume0.54 Prev Close3.12
ShortableYes LT Debt/Eq0.00 EarningsJul 23 BMO Payout- Avg Volume1.13M Price3.02
Recom1.40 SMA200.04% SMA5012.95% SMA20032.29% Volume516,626 Change-3.21%
Nov-15-19Initiated SVB Leerink Outperform $7
Jul-08-19Resumed Stifel Buy $13
Mar-01-19Reiterated Needham Buy
Feb-06-18Upgrade Needham Hold → Buy $3
Sep-27-17Downgrade Needham Buy → Hold
Sep-26-17Downgrade Stifel Buy → Hold $15 → $2.50
Jul-25-17Upgrade Needham Hold → Buy $12
Feb-17-17Downgrade Needham Buy → Hold
Apr-01-16Reiterated Stifel Buy $11 → $13
Dec-17-15Initiated UBS Buy $15
Oct-20-15Reiterated Needham Buy $22 → $15
Oct-19-15Reiterated FBR Capital Outperform $20 → $17
Mar-05-14Initiated Needham Buy $22
Mar-03-14Initiated Stifel Buy $25
Jul-30-20 07:00AM  
Jul-23-20 07:00AM  
Jul-22-20 09:02AM  
Jul-20-20 08:00AM  
Jul-16-20 08:00AM  
Jul-06-20 09:27AM  
Jun-23-20 03:52PM  
Jun-22-20 09:00AM  
Jun-15-20 07:30AM  
May-29-20 08:00AM  
May-19-20 07:30AM  
May-13-20 06:02PM  
07:40AM  
May-12-20 05:32PM  
May-11-20 04:30PM  
May-05-20 04:05PM  
Apr-30-20 07:00AM  
Apr-24-20 06:11AM  
Apr-23-20 08:01PM  
11:44AM  
Apr-21-20 07:00AM  
Apr-08-20 04:01PM  
Feb-26-20 04:05PM  
Feb-20-20 09:15PM  
08:00AM  
Feb-13-20 07:00AM  
Feb-06-20 07:30AM  
Dec-14-19 09:43PM  
Nov-14-19 05:00PM  
08:30AM  
Nov-09-19 09:00AM  
Nov-05-19 08:05AM  
Oct-29-19 07:22AM  
Oct-24-19 07:00AM  
Oct-17-19 08:00AM  
Sep-30-19 01:13PM  
Sep-27-19 08:00AM  
Sep-18-19 09:31AM  
Aug-30-19 08:00AM  
Aug-24-19 01:46PM  
Aug-05-19 01:13PM  
Jul-25-19 07:00AM  
Jul-18-19 08:00AM  
Jun-25-19 08:37AM  
Jun-24-19 01:58PM  
Jun-20-19 09:52AM  
Jun-18-19 04:04PM  
Jun-03-19 12:47PM  
10:45AM  
09:17AM  
07:00AM  
May-31-19 12:44PM  
08:00AM  
May-23-19 05:34PM  
May-16-19 01:00PM  
08:00AM  
Apr-30-19 08:13AM  
08:00AM  
Apr-23-19 08:00AM  
Apr-03-19 04:01PM  
Apr-02-19 01:00PM  
Mar-20-19 10:38AM  
Mar-19-19 11:52AM  
Mar-13-19 08:23AM  
Mar-07-19 08:18AM  
Mar-06-19 08:05AM  
Feb-28-19 08:00AM  
Feb-21-19 08:00AM  
Feb-12-19 08:30AM  
Jan-30-19 02:21PM  
Jan-02-19 11:55AM  
08:00AM  
Dec-14-18 12:14PM  
Dec-10-18 08:00AM  
Nov-27-18 08:40AM  
Nov-15-18 08:00AM  
Nov-06-18 07:10PM  
08:00AM  
Nov-01-18 08:35AM  
08:00AM  
Oct-25-18 08:05AM  
Oct-19-18 03:07PM  
Oct-11-18 08:35AM  
Oct-09-18 08:35AM  
Oct-01-18 07:30AM  
Sep-24-18 08:02AM  
Aug-29-18 08:05AM  
Aug-16-18 05:41AM  
Aug-07-18 07:35AM  
Aug-02-18 03:18PM  
09:58AM  
08:04AM  
07:00AM  
Jul-26-18 08:05AM  
Jul-11-18 07:35AM  
Jun-01-18 08:04AM  
May-10-18 09:02AM  
07:59AM  
May-04-18 08:04AM  
May-02-18 07:45AM  
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient's CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sonsini Peter W.10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:26 PM
Walker Paul Edward10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:26 PM
SANDELL SCOTT D10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:25 PM
Makhzoumi Mohamad10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:23 PM
MAKOWER JOSHUA10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:24 PM
Florence Anthony A. Jr.10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:23 PM
Behbahani AliDirectorJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:22 PM
Chang Carmen10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:22 PM
New Enterprise Associates 16, 10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:19 PM
BASKETT FOREST10% OwnerJul 24Buy2.253,151,2607,090,33510,376,936Jul 28 05:20 PM
GLAXOSMITHKLINE PLC10% OwnerJul 24Buy2.251,260,5042,836,1344,626,389Jul 30 08:56 PM